- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Treatment with ranibizumab in aflibercept inadequate AMD responders led to visual acuity improvement: The "ELEVATE" Study
Age-related macular degeneration (AMD) is a progressive, degenerative disease of the retina, and a leading cause of vision loss worldwide. Vascular endothelial growth factor (VEGF) plays a pivotal role in the pathogenesis of CNV. As a result, the introduction of anti-VEGF agents for the treatment of wAMD has drastically altered the standard of care in retinal medicine, substantially lowering the rates of legal blindness and visual impairment. Four anti-VEGF agents have been evaluated for the treatment of wAMD: pegaptanib, bevacizumab, ranibizumab, and aflibercept, of which ranibizumab and aflibercept are those most commonly used in routine care.
Rouvas et al carried a non-interventional, prospective study mainly aimed to provide real-world data on the six month effects of ranibizumab on anatomical and visual acuity outcomes in eyes with active neovascular AMD, that were previously treated with aflibercept and showed inadequate response, in a representative sample of patients treated in the routine care of Greece.Prospective, observational study performed in eight ophthalmology hospital/private clinics in Greece, enrolling consented patients with active wAMD, ≥50 years-old, who had initiated ranibizumab ≥28 days and < 2 months after their last aflibercept injection. Data were collected at enrollment, and at 1, 3 and 6 months post-treatment onset (post-baseline).
Between September-2015 and November-2017, 103 eligible patients were consecutively enrolled. The age at AMD diagnosis in the study eye was 71.3±8.8 years.
Aflibercept (median of 5 injections received over 11.3 months) had been discontinued for anatomical (in 69.9%) and/or functional (38.8%) reasons.
At baseline (median: 24.3 months after wAMD diagnosis), choroidal neovascularization was occult in 69.1% of evaluable study eyes; 60.2% of the study eyes had pigment epithelial detachment (PED); 42.7% cysts; 21.4% fibrosis; 66.0% subretinal, and 59.2% intraretinal fluid.
At 6 months post-baseline: a median of 3 ranibizumab injections (range: 1–6) had been received; the best-corrected visual acuity (BCVA)≥0 letter gain rate was 81.8%; the BCVA ≥15 letter gain rate was 17.0%; BCVA gain was 3.2 letters [mean increase: 3.2±10.0 letters; median: 0.0; p = 0.002]; PED greatest basal diameter (GBD; median: 1470.5 μm) also decreased (median decrease: 114.0 μm; p = 0.019). Baseline central retinal thickness (CRT; median: 312.0 μm) remained unchanged.
One patient permanently discontinued ranibizumab due to adverse event occurrence, assessed as not causally related to ranibizumab. There were no ranibizumab-related adverse reactions.
The study indicates that ranibizumab improves visual acuity and certain anatomic outcomes after only 6 months of treatment, even when fewer than the recommended injections are administered. Additionally, physicians ranked the ease of administration of ranibizumab as better (58%) or the same (39%) as that of aflibercept in the vast majority of the patients.
Regarding anatomic outcomes, CRT remained stable throughout the observation period, whereas a statistically significant mean decrease of 46.5 μm in PED height from baseline to 6 months (using LOCF imputation) was noted (matching the 46-μm mean change assumed for sample size estimation), while significant mean decreases were also observed in PED GBD of 114.0 μm based on as-observed data and of 143.0 μm using LOCF imputation.
Overall, the study demonstrated that in the routine care of Greece, patients with wAMD receive fewer ranibizumab injections than those that would be administered under the approved dosage schedule. Under these conditions, after approximately 6 months of treatment, the patients' visual acuity improved, modest improvements in PED dimensions were noted, and CRT remained stable Further real-world evidence is needed from studies more closely matching the approved dosage scheme, in order to identify predictors of early response, aiming to enhance outcomes in patients with wAMD who have inadequately responded to prior aflibercept treatment and to further delay the progression of the disease.
Source: Rouvas et al; Clinical Ophthalmology 2022:16
Dr Ishan Kataria has done his MBBS from Medical College Bijapur and MS in Ophthalmology from Dr Vasant Rao Pawar Medical College, Nasik. Post completing MD, he pursuid Anterior Segment Fellowship from Sankara Eye Hospital and worked as a competent phaco and anterior segment consultant surgeon in a trust hospital in Bathinda for 2 years.He is currently pursuing Fellowship in Vitreo-Retina at Dr Sohan Singh Eye hospital Amritsar and is actively involved in various research activities under the guidance of the faculty.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751